Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors (vol 27, pg 3620, 2021)

被引：1
|
作者：
Curigliano, Giuseppe
Curigliano, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 17期
关键词：
D O I：
10.1158/1078-0432.CCR-24-2131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3957 / 3957
页数：1
相关论文
共 50 条
  • [21] Open-label, phase I, dose escalation/expansion trial of the anti-SIRPa monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
    Gutierrez, M.
    Jamal, R.
    Yamamoto, N.
    Doi, T.
    Elgadi, M.
    Ferrada, J. L.
    Wojciekowski, S. M.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S485 - S485
  • [22] A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
    Harding, James J.
    Patnaik, Amita
    Moreno, Victor
    Stein, Mark
    Jankowska, Anna M.
    de Mendizabal, Nieves Velez
    Liu, Zhuqing Tina
    Koneru, Mythili
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [23] Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
    Chen, Gang
    Sun, Dong-Chen
    Ba, Yi
    Zhang, Ya-Xiong
    Zhou, Ting
    Zhao, Yuan-Yuan
    Zhao, Hong-Yun
    Fang, Wen-Feng
    Huang, Yan
    Wang, Zhen
    Deng, Chao
    Hu, De-Sheng
    Wang, Wei
    Lin, Jin-Guan
    Li, Gui-Ling
    Luo, Su-Xia
    Fu, Zhi-Chao
    Zhu, Hai-Sheng
    Wang, Hui-Li
    Cai, Sheng-Li
    Kang, Xiao-Qiang
    Zhang, Li
    Yang, Yun-Peng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [24] AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS
    El-Khoueiry, Anthony
    Bullock, Andrea
    Tsimberidou, Apostolia
    Mahadevan, Daruka
    Wilky, Breelyn
    Twardowski, Przemyslaw
    Bockorny, Bruno
    Moser, Justin
    Feliu, Waldo Ortuzar
    Grossman, Joseph
    Rosenthal, Katherine
    O'Day, Steven
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A509 - A509
  • [25] Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
    Desai, Jayesh
    Deva, Sanjeev
    Lee, Jong Seok
    Lin, Chia-Chi
    Yen, Chia-Jui
    Chao, Yee
    Keam, Bhumsuk
    Jameson, Michael
    Hou, Ming-Mo
    Kang, Yoon-Koo
    Markman, Ben
    Lu, Chang-Hsien
    Rau, Kun-Ming
    Lee, Kyung-Hun
    Horvath, Lisa
    Friedlander, Michael
    Hill, Andrew
    Sandhu, Shahneen
    Barlow, Paula
    Wu, Chi-Yuan
    Zhang, Yun
    Liang, Liang
    Wu, John
    Paton, Virginia
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [26] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [28] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
    J. Randolph Hecht
    Jean-Marie Michot
    David Bajor
    Amita Patnaik
    Ki Y. Chung
    Judy Wang
    Gerald Falchook
    James M. Cleary
    Richard Kim
    Anuradha Krishnamurthy
    Omkar Marathe
    Hagop Youssoufian
    Catherine Ellis
    Angela Waszak
    Srimoyee Ghosh
    Hailei Zhang
    Kaitlin Yablonski
    Shruti D. Shah
    Ivan Diaz-Padilla
    Susanna Ulahannan
    BJC Reports, 3 (1):
  • [29] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [30] PHASE 1 TRIAL OF FIRST-IN-CLASS ANTI-CD96 MONOCLONAL ANTIBODY INHIBITOR, GSK6097608, MONOTHERAPY AND COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY, DOSTARLIMAB, IN ADVANCED SOLID TUMORS
    Hamid, Omid
    Baxter, Dawn
    Easton, Rachael
    Siu, Lilian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A518 - A518
12345